Ritholtz Wealth Management Lowers Stock Holdings in Novo Nordisk A/S $NVO

Ritholtz Wealth Management lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 19.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,739 shares of the company’s stock after selling 14,443 shares during the period. Ritholtz Wealth Management’s holdings in Novo Nordisk A/S were worth $2,989,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. Revolve Wealth Partners LLC grew its position in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the period. AQR Capital Management LLC grew its position in shares of Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC grew its position in shares of Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after purchasing an additional 1,587 shares during the period. Invesco Ltd. grew its position in shares of Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after purchasing an additional 87,467 shares during the period. Finally, Gamco Investors INC. ET AL purchased a new stake in shares of Novo Nordisk A/S in the second quarter valued at $314,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Short interest fell sharply in March (about a 19% drop vs. mid‑March), lowering near‑term bearish pressure and reducing potential short‑covering risk. (Source: recent short‑interest report)
• Positive Sentiment: EMA cleared an update allowing Wegovy injections to be delivered at up to 30°C for 48 hours, which should improve distribution flexibility and lower logistics costs in Europe — a modest operational tailwind. Wegovy EMA approval
• Positive Sentiment: Wegovy’s oral formulation appears to be expanding the obesity treatment market by drawing new patients (not just switching injection users), supporting longer‑term demand potential for Novo’s GLP‑1 franchise. CNBC short on Wegovy pill
• Neutral Sentiment: Positive buy‑and‑hold coverage and listings naming Novo as a top growth stock provide long‑term investor support but do not address near‑term competitive or pricing issues. Yahoo piece on growth thesis
• Neutral Sentiment: Novo Holdings (the controlling shareholder) is adding investments outside pharma (e.g., superconductors), which is a corporate/portfolio move with limited direct impact on Novo Nordisk’s operational outlook. Novo Holdings investment
• Negative Sentiment: Eli Lilly launched its once‑daily oral GLP‑1 (Foundayo) broadly in the U.S., increasing competitive pressure on Novo’s market share and pricing power in weight‑loss treatments. Foundayo availability
• Negative Sentiment: Reports of cheap semaglutide generics in India are eroding pricing power in key markets and could weigh on longer‑term revenue if generics expand beyond regional markets. India generics report
• Negative Sentiment: UBS and other analysts warn Q1 results (May 6) will be the first meaningful read on economics at new, lower GLP‑1 price points; coupled with a disappointing CagriSema trial and below‑consensus 2026 guidance earlier this year, this raises near‑term earnings risk. UBS pricing test note
• Negative Sentiment: Media and commentators highlight Eli Lilly pulling ahead in the obesity drug race, which can weigh on sentiment and relative valuation for Novo in the near term. 247WallSt comparison

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $37.52 on Monday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The stock has a market capitalization of $167.51 billion, a P/E ratio of 10.81, a PEG ratio of 8.85 and a beta of 0.73. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The business’s fifty day moving average price is $41.03 and its 200 day moving average price is $48.92.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were issued a $1.2751 dividend. The ex-dividend date was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 50.43%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NVO. Citigroup began coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Finally, Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. Four research analysts have rated the stock with a Buy rating and twenty have given a Hold rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.